Apollomics : BIO 2024 Presentation

June 2024 I Nasdaq: APLM

Corporate Presentation

2024 BIO International Convention

Forward-Looking Statements

This presentation is for informational purposes only and shall not constitute an offer to purchase, sell or exchange any security, a solicitation of any offer to purchase, sell or exchange any security, or a recommendation or advice regarding any security of Apollomics, Inc. ("we," "us," "our" or the "Company"), nor shall there be any sale of any securities of the Company in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Sales and offers to sell securities of the Company will only be made in accordance with the Securities Act of 1933, as amended (the "Securities Act"), and applicable Securities and Exchange Commission ("SEC") regulations.

This presentation is being delivered on a confidential basis and is intended solely for the information of the persons to whom it is presented. It may not be retained, reproduced or distributed, in whole or in part, by any means (including electronic) without the prior written consent of the Company. By receiving this presentation, you understand and agree that the fact that this meeting has taken place and anything you hear or learn during this meeting are strictly confidential.

This presentation includes statements that constitute "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of present or historical fact included in this presentation, regarding the Company's future financial performance, as well as the Company's strategy, future operations, revenue guidance, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this presentation, the words "could," "should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this presentation are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States and China affecting Apollomics' operations and the continued listing of Apollomics' securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics' oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to protect Apollomics' intellectual property; (v) breaches in data security; (vi) the risk that Apollomics may not be able to maintain effective internal controls; (vii) unfavorable changes to the regulatory environment; and (viii) those risks and uncertainties discussed in the Apollomics' Annual Report on Form 20-F for the year ended December 31, 22, filed with the SEC on April 28, 2023, under the heading "Risk Factors" and the other documents filed, or to be filed, by the Company with the SEC. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results and/or could

cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. Should one or more of the risks or uncertainties described in this presentation materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. New risk factors that may affect actual results or outcomes emerge from time to time and it is not possible to predict all such risk factors, nor can Apollomics assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements.

Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC's website at www.sec.gov. Apollomics undertakes no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If Apollomics updates one or more forward-looking statements, no inference should be drawn that Apollomics will make additional updates with respect to those or other forward-looking statements.

This presentation contains discussions of investigational products that are under preclinical or clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration ("FDA"). Investigational products are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.

This presentation contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the ® or™ symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

This presentation does not purport to contain all of the information that may be required to evaluate all of the factors that would be relevant to you in considering any potential transaction and you should conduct your own investigation and analysis. This presentation is for informational purposes and reference only pursuant to your request and is not intended to be, and must not be, taken as the basis for a decision with respect to any possible transaction. Neither the Company nor any of its affiliates or representatives makes any representation or warranty, expressed or implied, as to the accuracy or completeness of this presentation or any of the information contained herein, or any other written or oral communication transmitted or made available to you or your affiliates or representatives. The Company and its affiliates or representatives expressly disclaim to the fullest extent permitted by law any and all liability based, in whole or in part, on the presentation or any information contained herein, or any other written or oral communication transmitted or made available to you or your affiliates or representatives, including, without limitation, with respect to errors therein or omissions therefrom.

This Presentation is not intended to form the basis of any investment decision by you and does not constitute investment, tax or legal advice.

2

Company Highlights

Innovative biotechnology company focusing on developing oncology therapies that target specific molecular pathways to enhance standard-of-care

Vebreltinib - near-term NDA opportunities

Strategic Partnerships to expand indications

Finance

Vebreltinib - a highly potent, de-risked and differentiated MET Inhibitor with best-in- and first-in-class potentials

• Pivotal Phase 2 SPARTA in MET dysregulated lung and brain cancers with multiple anticipated near-term clinical and regulatory catalysts
• Clear regulatory path forward with NDA submission(s) in 2025/2026
• Recently approved in China as monotherapy in 2 indications by Avistone

Strategic collaborations allow to expand indications and broaden market potential

Company based in the U.S. with clinical trial sites across 10+ countries

Listed on Nasdaq (APLM) in March 2023

$45M cash* runway through mid-2025

* As of December 31, 2023; pro forma for May 2024 financing	3

Robust and Differentiated Pipeline with Multiple Upcoming Catalysts

Drug Candidate

IP Rights

Mono /Combo

Indications

Preclinical

IND

Phase 1

Phase 2

Phase 3

Recent/ Anticipated Milestones

Data update and FDA meeting

MET Exon 14 NSCLC

Pivotal Phase 2

SPARTA Global

Q3/Q4 '24; Approved in China

Nov 23 (Avistone)

Mono

MET amplified NSCLC

Pivotal Phase 2

SPARTA Global Study

Data update 1H 2025

Vebreltinib (APL-101)

Global1

(c-MET inhibitor)

MET fusion GBM

Phase 2 SPARTA

Global Study

Avistone Data at ASCO 2024;

FDA Orphan Drug Designation

Approved in China Apr 24

+ EGFR

2L EGFR + MET NSCLC

Phase 2 SPARTA

Global Study

inhibitors

+ Osimertinib

1L EGFR + MET NSCLC

Investigator-initiated Proof of Concept Trial

Data update Q3/Q4 '24

(EGFR inhibitor)

Uproleselan (APL-106)

r/r AML, newly diagnosed

Completed enrollment Q4 '23 with

(E-Selectin inhibitor)

China

+ Chemo

Phase 3 Bridging Study in r/r AML in China-

AML

anticipated readout in 1H 2025

NMPA Breakthrough Designation

APL-122 (ErbB1/2/4 inhibitor)

Global2

Mono

ErbB1/2/4 positive cancers

Phase 1 Dose

Escalation and Expansion Study

Readout 2025

APL-102 (Multiple Kinases

Global

Mono

Solid tumors

Phase 1 Dose

Escalation and Expansion Study

Readout 2025

inhibitor)

APL-108(E-Selectin inhibitor)

China

+ Chemo

To Be Announced

U.S. partner GlycoMimetics

Completed Phase 1 study

APL-502(PD-L1 targeting mAb)

Global3

Mono

Multiple tumor types

China partner CTTQ's NDA approved

in Q2 '24

APL-810(G-17 neutralizing mAb)

US,China

Mono

Gastrointestinal (GI) cancers

TBD

EGFR -epidermal growth factor receptor; IP - intellectual property; GBM - glioblastoma multiforme;			4
r/r AML - relapsed or refractory acute myeloid leukemia; NSCLC - non-small cell lung cancer.	Tumor Inhibitors	Anti-Cancer Enhancers	Immuno-oncology Drugs
1Excluding China, Hong Kong and Macau. 2Excluding China, Hong Kong and Taiwan. 3Excluding China.

Vebreltinib in NSCLC and GBM

MET inhibitor

MET Dysregulations in Cancer - Multiple Therapeutic Opportunities

c-MET is a receptor tyrosine kinase found on epithelial cells in many organs

Hepatocyte Growth Factor (HGF)

Mutation Type		Outcome

Indication Incidence

Cancer- causing

MET

Treatment- resistance

causing

Motility Migration Proliferation Invasion

Rarely co-occur

MET Exon14		Extended signaling
Skipping
		Higher number of
MET Amplification
(de novo)		receptors signaling
		HGF-independent
PTPRZ1-MET Fusions
	signaling
MET amplification		Higher number of
(acquired)		receptors signaling

NSCLC with MET Exon-

14 skipping

MET Amplified NSCLC (de novo)

GBM with PTPRZ1- MET Fusions

EGFRm NSCLC MET

Amplified (acquired)

15-50% of NSCLC progressed on EGFR, ALK, ROS1, KRASi

6

Vebreltinib: A Highly Specific MET Inhibitor, Benchmarked vs. Capmatinib

Vebreltinib

Capmatinib

Vebreltenib has stronger binding due to difluoromethylene

substitutes for the Val 1092 hydrophobic pocket

Screening of 100 kinases at 2 µM single dose

• Unique structure and biopharmaceutical properties to effectively inhibit MET

• Only inhibits c-Met in screening of 473 kinases at 1 µM

• Ki = 2.2 nM on inhibition of in vitro enzyme activity

Poster #2096 AACR 2017 and Internal data

7

Pivotal Phase 2 SPARTA Trial Design

Global, multi-cohort,single-arm, open label Phase 2 Study to support multiple indications*

	Screening	Vebreltinib 200 mg BID 28-day cycle	Follow-Up Until
	Progression
	Mutation	Cohort / Indication
		NSCLC 1L (MET inhibitor naïve)
	MET Exon14 Skipping
	NSCLC 2L/3L (MET inhibitor naïve)
			Primary endpoint:
Cancer-causing	MET Amplification	NSCLC harboring MET amplification and wild-type EGFR (MET
ORR based on
	(de novo)	inhibitor naïve)
	RECIST 1.1
			supported by DOR
	PTPRZ1-MET Fusions	Primary CNS tumors with MET alterations (MET inhibitor naïve)
Treatment-	MET Amplification	EGFR mutated NSCLC with acquired MET amplification
resistance
(acquired)	(combo)
causing

*Other cohorts included in the Phase 2 SPARTA trial (not currently recruiting)are: cohort C: Basket of tumor types except primary CNS tumors, MET amplification (MET inhibitor naïve);

8

cohort D: Basket of tumor types except primary CNS tumors, harboring MET gene fusions (METi naïve); cohort F: Basket of tumor types with over expression of HGF & Over-expression of MET; MET WT.

NSCLC with

MET Ex14 Skipping

Vebreltinib

NSCLC	NSCLC
Ex14 Skipping	Amp+

Vebreltinib Demonstrated a Robust Response Rate in Patients with MET Ex14 Skip NSCLC

r/r GBM

MET-Fusion

		1L NSCLC Patients			2L+ NSCLC Patients
MET Ex14 Skip NSCLC
SPARTA-II	KUNGPENG	Combined	SPARTA-II**	KUNGPENG		Combined
CCAS*
(N=36)	(N=35)	(N=71)	(N=19)	(N=17)		(N=36)
Confirmed ORR	55.6%	77.1%	66.2%	52.6%	70.6%		61.1%
95% CI	(38.1, 72.1)	(59.9, 89.6)	(54.0, 77.0)	(28.9, 75.6)	(44.0, 89.7)		(43.5, 76.9)
mDOR (Months)	11.2	17.1	16.5	10.6	16.7		16.7
95% CI	6.0, NE	9.2, NE	9.2, 23.0	1.1, NE	3.7, NE		5.4, NE
DOR >= 12 Months	35.8%	60.5%	52.2%	30.9%	61.4%		53.8%
DCR (%)	91.7%	97.1%	94.4%	73.7%	94.1%		83.3%
95% CI	(77.5, 98.2)	(85.1, 99.9)	(86.2, 98.4)	(48.8, 90.9)	(71.3, 99.9)		(67.2, 93.6)

*Patients who first dosed prior to 2023-05-31 in SPARTA-II CCAS population and patients who first dosed prior to 2021-12-31 in KUNGPENG are included. ** Patients with last IO use <	10
90 days in SPARTA-II are excluded. Based on data available up to 2023-10-26. Patients with central tissue NGS confirmed MET Ex14 Skip NSCLC. NE - not estimable yet.